We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $728K invested in XTL Biopharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

201% more capital invested

Capital invested by funds: $242K → $728K (+$486K)

0.36% more ownership

Funds ownership: 4.39% → 4.75% (+0.36%)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$15.8K
2
UBS Group
UBS Group
Switzerland
+$7.97K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$693
2
CTC
Central Trust Company
Missouri
-$203

XTLB Hedge Fund Activity: Q1 2024 in Review

5 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2024, worth a combined $728K — up 201% from $242K a quarter earlier.

Fund positioning in XTLB was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $15.8K. The largest seller was Morgan Stanley, cutting an estimated $693.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $728K of XTL Biopharmaceuticals stock for Q1 2024, up 201% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q1 2024 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $15.8K added.
  • The largest XTL Biopharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $693 sold.

Based on aggregated 13F filings for Q1 2024.